Breaking News Instant updates and real-time market news.

CYAD

Celyad

$24.88

(0.00%)

, BLUE

Bluebird Bio

$122.91

-5.47 (-4.26%)

10:25
11/27/18
11/27
10:25
11/27/18
10:25

William Blair biotech analysts to hold an analyst/industry conference call

Biotech Analysts, along with Dr. Marco Davila of Moffitt Cancer Center, discuss the development of cell therapies in hematological malignancies on an Analyst/Industry conference call to be held on November 27 at 11 am.

CYAD

Celyad

$24.88

(0.00%)

BLUE

Bluebird Bio

$122.91

-5.47 (-4.26%)

NVS

Novartis

$88.01

-0.99 (-1.11%)

GILD

Gilead

$66.48

-0.48 (-0.72%)

CELG

Celgene

$67.52

-0.49 (-0.72%)

AUTL

Autolus Therapeutics

$39.20

-1.37 (-3.38%)

ALLO

Allogene Therapeutics

$27.20

-0.39 (-1.41%)

CLLS

Cellectis

$20.92

-0.37 (-1.74%)

  • 27

    Nov

  • 27

    Nov

  • 27

    Nov

  • 29

    Nov

  • 01

    Dec

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 03

    Dec

  • 10

    Dec

  • 13

    Dec

CYAD Celyad
$24.88

(0.00%)

11/12/18
PIPR
11/12/18
NO CHANGE
Target $51
PIPR
Overweight
Celyad price target lowered to $51 from $74 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Celyad to $51 after rolling forward his discount period to 2019. The analyst, however, keeps an Overweight rating on the shares after the company updated solid tumor data from the Think and Shrink studies of CYAD-01. Celyad will report Think data on 12 relapsed/refractory acute myeloid leukemia patients in December, Tenthoff tells investors in a research note. He also believes the company has enough cash to fund its operations through mid-2020.
10/30/18
WBLR
10/30/18
INITIATION
WBLR
Outperform
Celyad initiated with an Outperform at William Blair
William Blair analyst Raju Prasad started Celyad with an Outperform rating.
10/30/18
WBLR
10/30/18
INITIATION
WBLR
Outperform
William Blair starts Celyad with Outperform, $53 fair value estimate
William Blair analyst Raju Prasad initiated coverage of Celyad with an Outperform rating and $53 fair value estimate. Celyad's lead candidate, CYAD-01, is an autologous NKG2D chimeric antigen receptor (CAR)-T cell therapy being developed to treat both solid tumors and hematologic or liquid cancers, Prasad tells investors in a research note. The analyst believes the company's platform has several advantages, including a product profile that could be suitable for repeat injections, the ability to treat multiple tumor types using one CAR construct and the potential to show an adaptive immune response. Celyad's allogeneic platform is "significantly underappreciated," says Prasad.
07/02/18
07/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Howard Hughes (HHC) initiated with a Buy at Jefferies. 2. Celyad (CYAD) initiated with a Buy at H.C. Wainwright. 3. Veoneer (VNE) initiated with a Sector Perform at RBC Capital. 4. Melinta Therapeutics (MLNT) initiated with an Overweight at Cantor Fitzgerald. 5. Axon (AAXN) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BLUE Bluebird Bio
$122.91

-5.47 (-4.26%)

11/05/18
WEDB
11/05/18
NO CHANGE
Target $166
WEDB
Outperform
Bluebird Bio price target lowered to $166 from $204 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Bluebird Bio to $166 from $204, while reiterating an Outperform rating on the shares. The analyst looks forward to a catalyst-filled ASH for the company that will be highlighted by a first look at next-gen BCMA-CAR-T candidate bb21217 in multiple myeloma and initial results from its Phase 1 study of shRNAmiR-LLV gene therapy for sickle cell disease. Nierengarten also notes that Bluebird has provided an update on its SCD registration strategy following the recent FDA-ASH SCD clinical endpoints workshop. He believes that the update increases the program's probability of success, but also pushes out the program's development timeline at least two years.
11/05/18
JANY
11/05/18
UPGRADE
Target $170
JANY
Buy
Janney Montgomery Scott upgrades Bluebird Bio to Buy ahead of ASH
As previously reported, Janney Montgomery Scott analyst Yun Zhong upgraded Bluebird Bio to Buy from Neutral, stating that he does not believe any company-specific reasons were behind the weakness seen in the stock since the end of August. With the stock having lost over 40% from its March peak, Zhong now sees a much more favorable valuation and he also expects more detailed data to be provided at the ASH conference driving further stock outperformance. Zhong maintains a $170 fair value estimate on Bluebird Bio shares.
11/14/18
BERN
11/14/18
UPGRADE
BERN
Outperform
Bluebird Bio upgraded to Outperform from Market Perform at Bernstein
11/14/18
11/14/18
UPGRADE
Target $155

Outperform
Bluebird Bio upgraded to Outperform at Bernstein
As previously reported, Bernstein analyst Vincent Chen upgraded Bluebird bio to Outperform from Market Perform, with a $155 price target. The analyst notes that historically, he "liked the science, did not like the valuation, worried about competition." But valuation has come down significantly and competitive threats are increasingly appreciated, and he does not think competitors are likely to kill Bluebird's programs near-term.
NVS Novartis
$88.01

-0.99 (-1.11%)

11/19/18
GSCO
11/19/18
UPGRADE
GSCO
Conviction Buy
Novartis upgraded to Conviction Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Katherine Alexakis Friday evening upgraded Novartis to Buy from Neutral and added the shares to her firm's Conviction List. The analyst believes Novartis is entering a period of sustained sales growth, driven by a "reinvigorated" pharma business, recently launched products and late-stage pipeline assets. Alexakis sees a "more focused company with higher returns and growth, meriting a premium valuation to large-cap EU pharma."
11/26/18
COWN
11/26/18
UPGRADE
COWN
Outperform
Novartis upgraded to Outperform from Market Perform at Cowen
11/26/18
COWN
11/26/18
UPGRADE
Target $100
COWN
Outperform
Cowen upgrades Novartis to Outperform, calls stock a best idea for 2019
As reported previously, Cowen analyst Steven Scala upgraded Novartis to Outperform from Market Perform. The analyst called it his Best Idea for 2019 as the company has transformed its business to deliver big potential new drugs with upside potential. He also cites aggressive management and the recent underperformance of the shares. Scala raised his price target to $100 from $90 on Novartis shares.
11/26/18
11/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Neutral from Sell at MoffettNathanson analyst Craig Moffett citing valuation. 2. Cognizant (CTSH) upgraded to Buy from Neutral at Goldman Sachs with analyst James Schneider saying Improving revenue growth brings prospects for a stock "re-rating." 3. Regions Financial (RF) upgraded to Overweight from Neutral at JPMorgan with analyst Vivek Juneja saying he expects the company to benefit from commercial and industrial loan growth, low deposit beta and improved efficiency. 4. Intuit (INTU) upgraded to Outperform from Sector Perform at RBC Capital with analyst Ross MacMillan citing the findings from his most recent survey of tax filers which suggests that "do-it-yourself" tax preparation should gain share from assisted filings as a result of the latest tax code changes. 5. Novartis (NVS) upgraded to Outperform from Market Perform at Cowen with analyst Steven Scala saying he called it his Best Idea for 2019 as the company has transformed its business to deliver big potential new drugs with upside potential. He also cites aggressive management and the recent underperformance of the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GILD Gilead
$66.48

-0.48 (-0.72%)

10/26/18
JEFF
10/26/18
NO CHANGE
Target $95
JEFF
Buy
Gilead shares can rebound to $80 over next 6-9 months, says Jefferies
Jefferies analyst Michael Yee continues to think Gilead Sciences is being "underappreciated" following last night's "solid' Q3 results. Gilead is positioned well into 2019, Yee tells investors in a post-earnings research note. He sees several Phase III catalysts over the next 6-9 months that can help Gilead rebound back to $80 per share and closer to his unchanged price target of $95.
10/31/18
EVER
10/31/18
NO CHANGE
EVER
Outperform
Gilead sales not at risk from UnitedHealth promotions, says Evercore ISI
Evercore ISI analyst Umer Raffat attributes the pullback today in shares of Gilead Sciences (GILD) to concerns over the company's HIV franchise given UnitedHealth's (UNH) promotions of cheaper alternatives. UnitedHealth (UNH) is offering a rewards plan to patients starting with HIV medications to help promote the use of lower priced drugs, Jefferies analyst Michael Yee pointed out earlier today in a research note. Raffat, however, does not see risk to Gilead's sales from the promotions. UnitedHealth's is proposing a switch to two separate tablets, which is not in the HIV guidelines today, says the analyst. He keeps an Outperform rating on Gilead shares, which are down 6% to $68.00 in afternoon trading.
10/31/18
MZHO
10/31/18
NO CHANGE
Target $94
MZHO
Buy
Mizuho says concerns over UnitedHealth program impact on Gilead seem unwarranted
Mizuho analyst Salim Syed blames UnitedHealth's (UNH) introduction of a new a program, called "My ScriptRewards," that will try to convince plan participants to take a cheaper HIV regimen in return for $500 in debit cards for the weakness in shares of Gilead (GILD). However, the analyst views the worries as unwarranted, noting that Cimduo is the "common thread" between all of the regimens that UnitedHealth's program calls out and it is an inferior drug to Gilead's Biktarvy. Biktarvy is the backbone of the number one recommended regimen according to HHS treatment guidelines, noted Syed, who keeps a Buy rating and $94 price target on Gilead shares.
11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
CELG Celgene
$67.52

-0.49 (-0.72%)

11/26/18
JEFF
11/26/18
NO CHANGE
Target $115
JEFF
Buy
Celgene trades at lowest P/E in Biotech history, says Jefferies
At 6.5 times 2019 estimated earnings, Celgene trades at the lowest price-to-earnings multiple in the history of Biotech, Jefferies analyst Michael Yee tells investors in a research note. The stock has dropped since the Q3 report partially on some worries around the Juno deal but largely on Street sentiment worsening and lack of clarity on what's the catalyst other than it's cheap, which isn't a catalyst in a bear market, Yee tells investors in a research note. The analyst thinks "this changes as precedent suggests," but he admits that the "timing is difficult." Celgene is trading at the analyst's "no-pipeline" value of $65 per share. The stock "could be one to recover on an improved biotech tape," says Yee, who keeps a Buy rating on Celgene with a $115 price target. The stock closed Friday down 89c to $66.65.
11/07/18
PIPR
11/07/18
NO CHANGE
Target $200
PIPR
Overweight
BeiGene produced 'strong quarter of commercial execution', says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Overweight rating and $200 price target on BeiGene (BGNE) after its Q3 results, saying the company had produced another "strong quarter of commercial execution as the Celgene (CELG) products were up significantly". The analyst notes that these products' contribution may be small to overall valuation, but sees their positive performance as a sign of BeiGene's ability to commercialize future, larger product opportunities in China. Van Buren adds that the NDA filing for zanubrutinib has a "negligible effect" on his valuation.
11/01/18
PIPR
11/01/18
NO CHANGE
Target $75
PIPR
Overweight
Acceleron's Medalist, Believe data 'not surprising,' says Piper Jaffray
Piper Jaffray analyst Danielle Brill says Acceleron (XLRN), along with partner Celgene (CELG), will present the Phase 3 Medialist data at ASH this weekend, highlighting luspatercept's "impressive" and durable efficacy. Brill tells investors in a research note that she thinks the magnitude of benefit observed with luspatercept met the high expectations that had been set. Additionally, Phase 3 data from the Believe trial will also be presented in December, and while the trial has been much less of a focal point for investors, luspatercept also demonstrated statistically and clinically meaningful reductions in transfusion requirements for TDT patients, the analyst says. While impressive overall, Brill found no major surprises in the abstracts and that results from the trials were in-line with expectations. She maintains an Overweight rating and $75 price target on Acceleron shares.
AUTL Autolus Therapeutics
$39.20

-1.37 (-3.38%)

10/24/18
HCWC
10/24/18
INITIATION
Target $45
HCWC
Buy
Autolus Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started Autolus Therapeutics (AUTL) with a Buy rating and $45 price target. The stock is currently trading at a market capitalization of about $1.2B, which is a "significant discount" to the $2.7B market capitalization that the Street is valuing peer Allogene's (ALLO) "limited pipeline," Chattopadhyay tells investors in a research note. With a "slew of data releases between" ASH 2018 and ASH 2019, the analyst expects a :potential convergence in valuation."
07/27/18
07/27/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) reinstated with a Neutral at BofA/Merrill. 2. uniQure (QURE) initiated with an Overweight at Cantor Fitzgerald. 3. Autolus Therapeutics (AUTL) initiated with a Neutral at Goldman Sachs. 4. Pure Storage (PSTG) initiated with an Overweight at JPMorgan. 5. Plains All American (PAA) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/17/18
WBLR
07/17/18
INITIATION
WBLR
Outperform
William Blair starts Autolus Therapeutics with Outperform, $38 valuation
William Blair analyst Matthew Phipps initiated coverage of Autolus Therapeutics with an Outperform rating and $38 "risk-adjusted valuation." The company's next-generation CAR-T therapies "have the potential to become the best-in-class products across multiple indications," Phipps tells investors in a research note. He believes the company is positioned for long-term success through continued innovation.
07/26/18
GSCO
07/26/18
INITIATION
GSCO
Neutral
Autolus Therapeutics initiated with a Neutral at Goldman Sachs
ALLO Allogene Therapeutics
$27.20

-0.39 (-1.41%)

11/05/18
COWN
11/05/18
INITIATION
COWN
Outperform
Allogene Therapeutics initiated with an Outperform at Cowen
Cowen analyst Phi Nadeau initiated Allogene Therapeutics with an Outperform rating, calling it the leading company in the development of allogenic Car T therapies for the treatment of cancer. He expects the company to create much long-term shareholder value as its pipeline advances.
11/05/18
GSCO
11/05/18
INITIATION
Target $41
GSCO
Buy
Goldman starts Allogene with Buy rating, $41 price target
Goldman Sachs analyst Salveen Richter initiated coverage of Allogene Therapeutics with a Buy rating and $41 price target. The company is the leading clinical-stage company focused on genetically-engineered allogeneic T cell therapies, a potentially "curative" approach for cancer, Richter tells investors in a research note. He projects peak sales of ~$5B across Allogene's three programs, which include ALLO-501 in non-Hodgkin lymphoma and ALLO-715 in multiple myeloma. Richter believes allogeneic CAR Ts are likely to replace the current autologous versions.
11/05/18
11/05/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Immunomedics (IMMU) initiated with an Overweight at Morgan Stanley. 2. Livent (LTHM) initiated with an Outperform at Credit Suisse and a Buy at Citi, Credit Suisse, BofA/Merrill, Goldman Sachs, and Nomura Instinet. 3. Allogene Therapeutics (ALLO) was initiated with an Outperform at Cowen, a Buy at Jefferies and Goldman Sach, as well as a Buy at Jefferies. 4. Linde plc (LIN) initiated with an Underperform at Bernstein and an Equal Weight at Barclays. 5. EnLink Midstream (ENLC) initiated with a Hold at Tudor Pickering. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/05/18
JPMS
11/05/18
INITIATION
Target $29
JPMS
Neutral
Allogene Therapeutics initiated with a Neutral at JPMorgan
JPMorgan analyst Cory Kasimov started Allogene Therapeutics with a Neutral rating and $29 price target. Given the 54% post-initial public offering rally, combined with the relatively early-stage nature of Allogene's key candidates, the analyst anticipates the stock may trade more in line with his broader universe in the interim. He believes, however, that the company's off-the-shelf CAR-T platform "has broad and disruptive potential" in oncology.
CLLS Cellectis
$20.92

-0.37 (-1.74%)

04/24/18
JEFF
04/24/18
NO CHANGE
Target $27
JEFF
Buy
Epizyme shares will bounce back, says Jefferies
Jefferies analyst Michael Yee says that while the partial clinical hold is a bad headline, shares of Epizyme (EPZM) will bounce back like Cellectis (CLLS), Juno and others did when they modified the protocol and trial brochures to get back up and running. After speaking to management, Yee thinks Epizyme's partial clinical hold will be lifted in a few months. Until then, however, the shares could be in the penalty box, the analyst tells investors in a research note. He keeps a Buy rating on Epizyme with a $27 price target.
07/16/18
LEHM
07/16/18
INITIATION
Target $50
LEHM
Overweight
Barclays starts Cellectis with Overweight rating, $50 price target
Barclays analyst Gena Wang initiated coverage of Cellectis S.A. with an Overweight rating and $50 price target. Following "impressive data" and several approvals of personalized autologous CAR-T cell therapies in various blood cancers, universal off-the-shelf allogeneic CAR-T would be future therapeutic approach with improved timeline, costs and homogeneity, Wang tells investors in a research note. As a leader in allo-CART with its proprietary Talen gene editing technology, Cellectis is the only company with clinical experience, on two programs, the analyst adds. She believes the company has a "strong" pipeline of allogeneic CAR-Ts targeting advanced blood cancers.
07/16/18
LEHM
07/16/18
INITIATION
Target $50
LEHM
Overweight
Cellectis initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Cellectis with an Overweight rating and $50 price target.
06/12/18
OPCO
06/12/18
NO CHANGE
Target $44
OPCO
Outperform
Cellectis price target raised to $44 from $40 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Cellectis to $44 from $40 after the company announced that the FDA approved its IND filing for UCART22 following a 30-day review period. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

09:00
12/17/18
12/17
09:00
12/17/18
09:00
General news
Treasury Action: yields stabilized above lows »

Treasury Action: yields…

08:58
12/17/18
12/17
08:58
12/17/18
08:58
General news
Futures pointing to extension of Friday selloff »

Stock futures are trading…

ADBE

Adobe

$230.00

-17.71 (-7.15%)

08:57
12/17/18
12/17
08:57
12/17/18
08:57
Conference/Events
RBC Capital Internet analysts to hold an analyst/industry conference call »

Internet Analysts discuss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 07

    Jan

LITE

Lumentum

$43.46

-0.4 (-0.91%)

, OCLR

Bought by LITE

$0.00

(0.00%)

08:56
12/17/18
12/17
08:56
12/17/18
08:56
Recommendations
Lumentum, Bought by LITE analyst commentary  »

Lumentum can continue…

LITE

Lumentum

$43.46

-0.4 (-0.91%)

OCLR

Bought by LITE

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKAM

Akamai

$65.08

-2.22 (-3.30%)

08:55
12/17/18
12/17
08:55
12/17/18
08:55
Conference/Events
Akamai management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

JNJ

Johnson & Johnson

$132.86

-14.94 (-10.11%)

, AAPL

Apple

$165.48

-5.45 (-3.19%)

08:55
12/17/18
12/17
08:55
12/17/18
08:55
Options
Notable open interest changes for December 17th »

Friday's total…

JNJ

Johnson & Johnson

$132.86

-14.94 (-10.11%)

AAPL

Apple

$165.48

-5.45 (-3.19%)

BAC

Bank of America

$24.49

0.1 (0.41%)

FB

Facebook

$144.02

-1.05 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 12

    Feb

08:55
12/17/18
12/17
08:55
12/17/18
08:55
General news
Trump back to Fed bashing on Twitter: »

Trump back to Fed bashing…

08:55
12/17/18
12/17
08:55
12/17/18
08:55
General news
The Empire State headline fell sharply »

The Empire State headline…

ANET

Arista Networks

$220.29

-8.46 (-3.70%)

08:52
12/17/18
12/17
08:52
12/17/18
08:52
Recommendations
Arista Networks analyst commentary  »

Needham calls Arista…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDOC

Teladoc

$51.16

-1.29 (-2.46%)

08:47
12/17/18
12/17
08:47
12/17/18
08:47
Earnings
Teladoc backs FY18 EPS view to ($1.48)-($1.50), consensus ($1.49) »

Backs FY18 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNDT

Conduent

$11.09

-0.17 (-1.51%)

08:47
12/17/18
12/17
08:47
12/17/18
08:47
Hot Stocks
Conduent unit selected to deploy next-gen fare collection system in Flanders »

Conduent Transportation,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$68.95

-0.69 (-0.99%)

, TBT

ProShares UltraShort 20+ yr Trsry

$37.20

-0.23 (-0.61%)

08:45
12/17/18
12/17
08:45
12/17/18
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

CMA

Comerica

$68.95

-0.69 (-0.99%)

TBT

ProShares UltraShort 20+ yr Trsry

$37.20

-0.23 (-0.61%)

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$65.98

3.66 (5.87%)

ALB

Albemarle

$84.96

-3.01 (-3.42%)

LULU

Lululemon

$119.13

-1.08 (-0.90%)

SVXY

ProShares Short VIX Short-Term Futures

$45.76

-0.95 (-2.03%)

SPWR

SunPower

$6.11

-0.18 (-2.86%)

HIMX

Himax

$3.64

-0.03 (-0.82%)

ZUO

Zuora

$18.23

0.13 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 14

    Jan

  • 15

    Jan

  • 16

    Jan

LZB

La-Z-Boy

$25.72

-0.5503 (-2.09%)

08:45
12/17/18
12/17
08:45
12/17/18
08:45
Upgrade
La-Z-Boy rating change  »

La-Z-Boy upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LION

Fidelity Southern

$21.36

-0.62 (-2.82%)

08:45
12/17/18
12/17
08:45
12/17/18
08:45
Hot Stocks
Breaking Hot Stocks news story on Fidelity Southern »

Fidelity Southern trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDOC

Teladoc

$51.16

-1.29 (-2.46%)

08:44
12/17/18
12/17
08:44
12/17/18
08:44
Hot Stocks
Teladoc CFO, COO Mark Hirschhorn to resign »

Teladoc announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALB

Albemarle

$84.96

-3.01 (-3.42%)

08:44
12/17/18
12/17
08:44
12/17/18
08:44
Conference/Events
Albemarle to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

LITE

Lumentum

$43.46

-0.4 (-0.91%)

08:44
12/17/18
12/17
08:44
12/17/18
08:44
Recommendations
Lumentum analyst commentary  »

Lumentum price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABCB

Ameris Bancorp

$34.02

-0.82 (-2.35%)

, LION

Fidelity Southern

$21.36

-0.62 (-2.82%)

08:43
12/17/18
12/17
08:43
12/17/18
08:43
Conference/Events
Ameris Bancorp to host conference call »

Conference call to…

ABCB

Ameris Bancorp

$34.02

-0.82 (-2.35%)

LION

Fidelity Southern

$21.36

-0.62 (-2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

INTC

Intel

$47.87

-0.42 (-0.87%)

08:41
12/17/18
12/17
08:41
12/17/18
08:41
Recommendations
Intel analyst commentary  »

Intel to be rewarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 08

    Jan

ACER

Acer Therapeutics

$17.50

-1.84 (-9.51%)

08:41
12/17/18
12/17
08:41
12/17/18
08:41
Hot Stocks
Acer Therapeutics appoints Salma Jutt as CCO »

Acer Therapeutic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:40
12/17/18
12/17
08:40
12/17/18
08:40
General news
FX Action: The dollar »

FX Action: The dollar…

08:40
12/17/18
12/17
08:40
12/17/18
08:40
General news
U.S. Empire State index dropped 12.4 points in December to 10.9 »

U.S. Empire State index…

PFG

Principal Financial

$43.62

0.37 (0.86%)

08:39
12/17/18
12/17
08:39
12/17/18
08:39
Conference/Events
Principal Financial management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

ANIX

Anixa Biosciences

$3.94

-0.05 (-1.25%)

08:39
12/17/18
12/17
08:39
12/17/18
08:39
Conference/Events
Anixa Biosciences to meet with the FDA »

Anixa Biosciences (ANIX)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

HJLI

Hancock Jaffe Laboratories

$1.79

0.02 (1.13%)

08:38
12/17/18
12/17
08:38
12/17/18
08:38
Hot Stocks
Hancock Jaffe Laboratories receives INVIMA approval for VenoValve trial »

Hancock Jaffe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.